Claims for Patent: 10,011,857

Summary for Patent: 10,011,857

Title:	Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated N-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
Abstract:	The invention provides mannosidases capable of uncapping mannose-1-phospho-6-mannose moieties and demannosylating phosphorylated N-glycans, methods of using such mannosidases, glycoproteins produced using the methods, as well as methods of facilitating mammalian cellular uptake of glycoproteins.
Inventor(s):	Piens; Kathleen Camilla Telesphore Alida Maria (Ghent, BE), Vervecken; Wouter (Landskouter, BE), Valevska; Albena Vergilieva (Astene, BE), Pynaert; Gwenda Noella (Aalter, BE)
Assignee:	Oxyrane UK Limited (Manchester, GB)
Application Number:	15/087,201
Patent Claims:	1. A method for uncapping mannose-1-phospho-6-mannose moieties and demannosylating phosphorylated N-glycans on a glycoprotein, said method comprising: a) providing said glycoprotein having phosphorylated N-glycans containing said mannose-1-phospho-6-mannose moiety; and b) contacting said glycoprotein with a single mannosidase that (i) hydrolyzes a mannose-1-phospho-6-mannose moiety to mannose-6-phosphate and (ii) hydrolyzes terminal alpha-1,2 mannose, alpha-1,3 mannose, or alpha-1,6 mannose linkages, wherein said single mannosidase is a Jack Bean mannosidase, wherein the method is performed in vitro. 2. The method of claim 1, wherein said glycoprotein is a human protein. 3. The method of claim 1, wherein said glycoprotein is a pathogen protein, a lysosomal protein, a growth factor, a cytokine, a chemokine, an antibody or antigen-binding fragment thereof, or a fusion protein. 4. The method of claim 3, wherein said lysosomal protein is a lysosomal enzyme. 5. The method of claim 4, wherein said lysosomal enzyme is acid alpha glucosidase or alpha galactosidase. 6. The method of claim 1, wherein said glycoprotein is associated with a lysosomal storage disorder (LSD. 7. The method of claim 6, wherein said LSD is Fabry's disease, mucopolysaccharidosis I, Farber disease, Gaucher disease, GM1-gangliosidosis, Tay-Sachs disease, Sandhoff disease, GM2 activator disease, Krabbe disease, metachromatic leukodystrophy, Niemann-Pick disease, Scheie disease, Hunter disease, Sanfilippo disease, Morquio disease, Maroteaux-Lamy disease, hyaluronidase deficiency, aspartylglucosaminuria, fucosidosis, mannosidosis, Schindler disease, sialidosis type 1, Pompe disease, Pycnodysostosis, ceroid lipofuscinosis, cholesterol ester storage disease, Wolman disease, Multiple sulfatase deficiency, galactosialidosis, mucolipidosis, cystinosis, sialic acid storage disorder, chylomicron retention disease with Marinesco-Sjogren syndrome, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, Danon disease, or Geleophysic dysplasia. 8. A method for uncapping mannose-1-phospho-6-mannose moieties and demannosylating phosphorylated N-glycans on a glycoprotein, said method comprising: a) providing said glycoprotein having phosphorylated N-glycans containing said mannose-1-phospho-6-mannose moiety; b) contacting said glycoprotein with a single mannosidase that (i) hydrolyzes a mannose-1-phospho-6-mannose moiety to mannose-6-phosphate and (ii) hydrolyzes terminal alpha-1,2 mannose, alpha-1,3 mannose, or alpha-1,6 mannose linkages, wherein said single mannosidase is a Jack Bean mannosidase; and c) contacting a mammalian cell with said glycoprotein comprising said demannosylated phosphorylated N-glycans, wherein, after said contacting, said glycoprotein is transported to the interior of said mammalian cell, wherein the method is performed in vitro. 9. The method of claim 8, wherein said mammalian cell is a human cell.

Details for Patent 10,011,857

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	May 05, 2004	10,011,857	2030-09-29
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	December 02, 2004	10,011,857	2030-09-29
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	October 26, 2004	10,011,857	2030-09-29